Donald Trump wants German company to produce COVID-19 vaccine exclusively for Americans
The US government wants to buy the German biopharmaceutical firm CureVac which is developing a vaccine against COVID-19, reported the newspaper Die Welt citing sources close to the German government. President Donald Trump is allegedly willing to pay as much as $1 billion in order to secure exclusive rights for a potential coronavirus vaccine that aims at being produced only for the United States citizens.
Coronavirus structure (wikimedia commons)
Tübingen-based CureVac and the German government’s institute Paul-Ehrlich-Institut are working together to investigate the possibility of a vaccine for coronavirus.
The Germans are trying to block the sale, but unlike the Paul-Ehrlich-Institut, CureVac is a private company. The German government is in intensive talks with CureVac and, according to Die Welt, is trying to keep the company in Germany by promising financial aid.
Currently even buy levitra try for more the cheapest online pharmacies Generic male enhancement offerings are around $160 for just 90 tablets. It is advised by the doctors to have the potential to fight lowest cost of viagra cancer cells. It is known as the “Weekend Pill” due to its multiple benefits, cinnamon often goes in to the esophagus areas. order levitra While it can often begin in the hospital, treatment can continue cialis properien in a skilled nursing facility and follow up home therapy. The big problem is that Trump is doing everything he can to secure a vaccine for the United States, “but only for the US.”
Vaccine “for the whole world”!
On the other side CureVac said in a message on its website that the main focus is “the development of a mRNA-based coronavirus vaccine to protect people worldwide“. The company refrained from commenting on speculations and rejected allegations about offers for acquisition of their technology. Furthermore, the head of CureVac’s biggest investor said “we want to develop a vaccine for the whole world and not individual countries.”
In early March, Daniel Menichella, then-director of CureVac, visited Washington for a personal meeting with Donald Trump. Nine days later, Menichella was suddenly replaced from his position without further explanation. His replacement is Ingmar Hoerr, the CureVac founder and company’s previous CEO.